Logotype for Novartis AG

Novartis (NOVN) investor relations material

Novartis Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Novartis AG
Q2 2025 earnings summary17 Jul, 2025

Executive summary

  • Achieved double-digit sales growth and core margin expansion in Q2 2025, leading to an upgrade in full-year bottom-line guidance.

  • Key launches such as Kisqali, Semblix, and Pluvicto accelerated, with robust execution across the portfolio and pipeline milestones reached.

  • Net sales rose to $14.1B in Q2, driven by strong US growth and key brands, partially offset by generic competition.

  • Announced CFO transition: Harry Kirsch to retire in 2026, Mukul Mehta named successor.

  • Focus remains on four core therapeutic areas and continued investment in emerging technology platforms and priority geographies.

Financial highlights

  • Q2 net sales grew 11–12% year-over-year to $14.1B; H1 net sales reached $27.3B, up 12–13%.

  • Core operating income up 21% in Q2 to $5.9B; core margin reached 42.2%, a 340 bps improvement.

  • Core EPS $2.42 in Q2, up 24%; H1 core EPS $4.69, up 27%.

  • Free cash flow for Q2 was $6.3B, up 37%; H1 free cash flow $9.7B–$10B, up 46%.

  • Net income increased 24–26% in Q2 to $4.0B.

Outlook and guidance

  • Upgraded full-year 2025 bottom line guidance: core operating income now expected to grow in the low teens (13–14%).

  • High single-digit sales growth expected for the full year.

  • Guidance assumes US Entresto generic entry mid-2025; each month of US Entresto sales worth $400M.

  • Core tax rate expected at 16–16.5%.

  • Q4 2025 growth expected to be impacted by prior-year one-time items and potential US generics impact.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Novartis earnings date

Logotype for Novartis AG
Q3 2025
LIVE
28 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Novartis earnings date

Logotype for Novartis AG
Q3 2025
LIVE
28 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Swiss Pharmaceuticals

Novartis International AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Established in 1996 through the merger of two companies, Novartis has cemented its place as one of the world's largest and most influential pharmaceutical companies with operations in over 150 countries. The company's portfolio includes a range of medicines, generic drugs, eye care devices, and consumer health products.

Roots in Swiss Pharmaceutical Companies

Novartis can trace its roots in two Swiss chemical companies, Ciba-Geigy and Sandoz, which had both been active in the global pharmaceutical industry for over a century before their merger. The fusion in 1996 aimed to leverage their combined strength in research and development, resulting in a global pharmaceutical behemoth. Novartis has since consistently ranked among the largest healthcare companies globally, partly due to its strong commitment to the development of new treatments.

A Diversified Pharmaceutical Powerhouse

Novartis operates under three main divisions: Innovative Medicines, Sandoz (generics), and Alcon (eye care). The Innovative Medicines division also referred to as the pharmaceuticals division, is dedicated to developing, manufacturing, and marketing patented prescription drugs. It includes two business units: Novartis Oncology and Novartis Pharmaceuticals, which target various therapeutic areas, including oncology, cardiology, respiratory, neuroscience, and ophthalmology, to name a few. Sandoz, the generics division of Novartis, provides high-quality, affordable medicines that treat some of the most prevalent healthcare issues. Lastly, the Alcon division focuses on eye care, manufacturing medical devices and products for eye care professionals and patients. They operate in the same field as companies such as Roche, Sanofi, Pfizer, and other large pharmaceutical companies.

Keeping Up With the Times

While remaining at the forefront of pharmaceutical innovation, Novartis continuously aims to refine its product portfolio and adapt to the ever-evolving healthcare landscape. The company has made significant strides in gene and cell therapies, most notably with Kymriah, a CAR-T cell therapy for certain types of blood cancers. Moreover, Novartis is working in digital health, employing data science and digital technologies to aid in drug discovery, patient care, and even the way clinical trials are conducted. The goal is to make treatments more personalized and more efficient, further enhancing patient outcomes.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage